One vs. two closure devices for TAVR access site
Part of Heart & circulation clinical trials.
This trial compares using one versus two Perclose devices to close the large hole in the leg after a TAVR procedure. It aims to find which method works better to prevent bleeding and other complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled for a TAVR procedure through the leg artery using a 14 French sheath and a CoreValve replacement valve.
- You do not have any major artery problems at the access site, such as a recent procedure or infection.
- You do not have a bleeding disorder or take blood thinners that can't be stopped safely.
- Your body mass index (BMI) is 35 or less.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device called xDot that helps close the small hole in the leg after a heart procedure like a valve replacement or aneurysm repair. It is a feasibility study, meaning the device is being tested for safety and how well it works in people.
This study compares two ways of closing the large artery in the groin after a TAVI procedure (a minimally invasive heart valve replacement). It aims to see which method is safer and more effective, which could help reduce bleeding and other complications.
This study tests a new device that seals the small hole in the groin artery after procedures like TAVI or EVAR. It aims to stop bleeding quickly and safely, helping you recover faster.
This trial compares two ways to treat a failing aortic valve that was replaced with a tissue valve during surgery: another surgical replacement or a less invasive catheter-based valve-in-valve procedure. It is for people with low to intermediate surgical risk who are between 18 and 75 years old.
This trial compares two different types of replacement heart valves (balloon-expandable vs. self-expanding) to see which works better for people with severe aortic stenosis. The goal is to find the best option for each patient.
This trial compares two newer types of replacement heart valves (SAPIEN 3 Ultra Resilia and Evolut FX) to see which one works better for people with severe aortic stenosis, a condition where the heart's main valve becomes narrow. If you join, you'll be randomly assigned to receive one of the two valves during your TAVI procedure.
Hear when a new Transcatheter Aortic Valve Replacement trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.